Skip to content
Company Analysis

Zevra Therapeutics, Inc. ZVRA

A comprehensive view of key metrics, scores, and financial health for Zevra Therapeutics, Inc.

Overview of Zevra Therapeutics, Inc.

ZVRA NMS
Healthcare Biotechnology Framework: Biotech / Pre-Revenue Small Cap
Zevra Therapeutics, Inc. (ZVRA), is a Small Cap company, in the Biotechnology industry, last closed at $10.05, about 41.4% overvalued vs fair value, -0.6% 1Y return, placing in the top 10% of its sector.
Metrics P/E 6.2× Rev Growth 350.9% ROE 85.7% Gross Margin 84.5%
USD 10.06
5.51%
(Delayed)
• Vol 90d: 67.2%
52-Week Range
Market Cap
$597.10M
Enterprise Value
$451.78M
Overall Score
View breakdown
Overall
Growth
Good
Profitability
Excellent
Health
Good
Efficiency
Good
Valuation
Good
Growth
Good
Profitability
Excellent
Health
Good
Efficiency
Good
Valuation
Good
Completeness: 88%
Confidence: 91%
Updated: Oct 24
Top Beats

Quick Facts

Website https://zevra.com
HQ Celebration, FL
Employees 59
Fiscal year Dec 31

Next Events

Earnings Nov 3 Call: Nov 3

Fair Value Snapshot

Bear Base Bull
$6
$6
$6
Current: $10.06 -41% vs base

Engine Room Money Flow™

Small Cap

Biotech / Pre-Revenue - Where revenue goes and how value is created

Flow Steps
Cash on Hand
$62.4M
84.7%%
Total Revenue
$106.5M
350.9%%
Net Income
$83.2M
178.9%%
Operating Expense
$94.2M
-8.7%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Biotech / Pre-Revenue

Quality & Reliability Indicators

Cash Runway
468.6 months
Excellent

Strong cash position with 2+ years of runway

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
1
Active Leaks
0/1
Improving
0
High Impact
0
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Zevra Therapeutics, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
57
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Consistent Cash Generation Cash generation is strong and consistent (score 0.86).
  • Cost Leadership Position Operating margin at 76.5th percentile with strong OpEx control demonstrates cost leadership.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
47
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Pre-Revenue Biotech vs Industry Peers 67% Coverage
Trade-Off Triangle Visualization A ternary plot showing ZVRA's balance between Growth (27.8%), Profitability (29.7%), and Safety (42.5%). Growth 28% Safety 43% Profitability 30%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

31th percentile vs peers
31
Key Signals
TSR -47.2% 31p
Strengths
  • Strong liquidity position vs peers
Risks
  • Growth below peer median (percentile: 31)

Profitability

- vs peers
-
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

47th percentile vs peers
48
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Zevra Therapeutics, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$5.90
- - -
-41.4% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000